Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Sara Z, Dejene"'
Autor:
Clara E. Busse, Chase D. Latour, Sara Z. Dejene, Andrea K. Knittel, Mollie E. Wood, Alan C. Kinlaw, Mekhala V. Dissanayake
Publikováno v:
Contraception: X, Vol 5, Iss , Pp 100101- (2023)
Objectives: Characterize new use of long-acting reversible contraceptives (LARCs), highly effective contraceptive methods, in a broad population over time. Study Design: We constructed a retrospective cohort of commercially insured individuals aged 1
Externí odkaz:
https://doaj.org/article/c988855fc9f34af8aea4d970243ebca9
Autor:
Ameet Sarpatwari, Beatrice L Brown, Sarah A McGraw, Sara Z Dejene, Abdurrahman Abdurrob, Aaron S Kesselheim
Publikováno v:
PLoS ONE, Vol 18, Iss 7, p e0288008 (2023)
PurposeThe US Food and Drug Administration (FDA) Amendments Act of 2007 authorized the FDA to require risk evaluation and mitigation strategy (REMS) programs for drugs with important safety concerns. REMS can have elements to assure safe use (ETASU),
Externí odkaz:
https://doaj.org/article/894db1850b21422fb7d26bac6d69b033
Publikováno v:
Female Pelvic Med Reconstr Surg
OBJECTIVES Although midurethral mesh slings are the criterion standard surgical treatment for stress urinary incontinence (SUI), limited data exist regarding long-term outcomes. Thus, our objectives were to evaluate the long-term risk of sling revisi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b59391435ae786d00296924dbdf8bf9
https://doi.org/10.1097/spv.0000000000001094
https://doi.org/10.1097/spv.0000000000001094
Autor:
Jennifer Cottral, Krista F. Huybrechts, David J. Combs, Kathryn J. Gray, Sonia Hernandez-Diaz, Devan Bartels, Beryl L. Manning-Geist, Sara Z. Dejene, Brian T. Bateman, Loreen Straub, Helen Mogun, Stacey Burns, Mengdong He, Rebecca M. Reimers
Publikováno v:
Pharmacoepidemiology and Drug Safety. 29:419-426
Background The Medicaid Analytic eXtract (MAX) is a health care utilization database from publicly insured individuals that has been used for studies of drug safety in pregnancy. Claims-based algorithms for defining many important maternal and neonat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efe14e03d0f04f62bf5de4f204a3a35f
https://doi.org/10.1002/pds.4967
https://doi.org/10.1002/pds.4967
Autor:
Ameet, Sarpatwari, Beatrice L, Brown, Sarah A, McGraw, Sara Z, Dejene, Abdurrahman, Abdurrob, Adrian J, Santiago Ortiz, Aaron S, Kesselheim
Publikováno v:
JAMA Network Open
This qualitative study examines patient and caregiver experiences with and perceptions of Risk Evaluation and Mitigation Strategy programs with Elements to Assure Safe Use.
Key Points Question How do patients and caregivers describe their experi
Key Points Question How do patients and caregivers describe their experi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1250ad2afc3a43aecf72801eedf9457f
https://doi.org/10.1001/jamanetworkopen.2021.44386
https://doi.org/10.1001/jamanetworkopen.2021.44386
Autor:
Brian T. Bateman, Rishi J. Desai, Krista F. Huybrechts, Elisabetta Patorno, Alexander M. Friedman, Michael A. Fischer, Sonia Hernandez-Diaz, Ellen W. Seely, Sara Z. Dejene, Helen Mogun
Publikováno v:
Obstetrics & Gynecology. 129:174-184
To examine the association between first-trimester angiotensin-converting enzyme (ACE) inhibitor exposure and the risk of overall major congenital, cardiac, and central nervous system malformations.We used a cohort of completed pregnancies linked to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55dc64e71ea9bacddf426c1ee2f9ec14
https://doi.org/10.1097/aog.0000000000001775
https://doi.org/10.1097/aog.0000000000001775
Autor:
Zhong Wang, Rishi J. Desai, Sarah K. Dutcher, Sara Wittayanukorn, Ameet Sarpatwari, Sara Z. Dejene, Joshua J. Gagne, Chandrasekar Gopalakrishnan, Raisa Levin, Jessica M. Franklin
Publikováno v:
Clinical pharmacology and therapeutics. 107(6)
The anticoagulant response to warfarin, a narrow therapeutic index drug, increases with age, which may make older patients susceptible to adverse outcomes resulting from small differences in bioavailability between generic and brand products. Using U
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de8a1a0e8ba3bc3cc7d79aaadc8cc733
https://pubmed.ncbi.nlm.nih.gov/31872419
https://pubmed.ncbi.nlm.nih.gov/31872419
Autor:
Rishi J. Desai, Aaron S. Kesselheim, Sarah K. Dutcher, Joshua J. Gagne, Joyce Lii, John G. Connolly, Nazleen F. Khan, Sara Z. Dejene, Ameet Sarpatwari, Saeid Raofi, Justin Bohn, James R. Rogers, Michael A. Fischer
Publikováno v:
PLoS Medicine
PLoS Medicine, Vol 16, Iss 3, p e1002763 (2019)
PLoS Medicine, Vol 16, Iss 3, p e1002763 (2019)
Background To the extent that outcomes are mediated through negative perceptions of generics (the nocebo effect), observational studies comparing brand-name and generic drugs are susceptible to bias favoring the brand-name drugs. We used authorized g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::342b7ce04e015f66149c8b742f94338c
https://pubmed.ncbi.nlm.nih.gov/30865626
https://pubmed.ncbi.nlm.nih.gov/30865626
Autor:
Ameet Sarpatwari, Rishi J. Desai, Sebastian Schneeweiss, Chandrasekar Gopalakrishnan, Sara Z. Dejene, Jessica M. Franklin, Raisa Levin, Joshua J. Gagne, Sarah K. Dutcher
Publikováno v:
Clinical pharmacology and therapeutics. 105(6)
Methodologic research evaluating confounding due to socioeconomic status (SES) in observational studies of medications is limited. We identified 7,109 patients who initiated brand or generic atorvastatin from Medicare claims (2011-2013) linked to ele
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f20df96116dc2fdebf15d66d61d76750
https://pubmed.ncbi.nlm.nih.gov/30659590
https://pubmed.ncbi.nlm.nih.gov/30659590
Autor:
Aaron S. Kesselheim, Saeid Raofi, Joshua J. Gagne, Michael A. Fischer, Justin Bohn, Ameet Sarpatwari, John Connolly, James R. Rogers, Rishi J. Desai, Joyce Lii, Nazleen F. Khan, Sara Z. Dejene, Sarah K. Dutcher
Publikováno v:
The BMJ
Objectives To compare rates of switchbacks to branded drug products for patients switched from branded to authorized generic drug products, which have the same active ingredients, appearance, and excipients as the branded product, with patients switc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ceeb32755e08e36925d4f55818889b7
http://europepmc.org/articles/PMC5881140
http://europepmc.org/articles/PMC5881140